Novavax Inc

NVAX

Equity

ISIN null / Valor 47862952

NASDAQ (2025-11-19)

USD 6.34-3.50%

Novavax Inc
UMushroom community rating:

3.17 4 votes No rating yet

NegativeNeutralPositive

About company

Novavax Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Leveraging proprietary recombinant nanoparticle vaccine technology, Novavax has been at the forefront of developing vaccines for a range of infectious diseases, including its notable efforts in creating a vaccine for COVID-19. The company's approach combines the power of genetic engineering and nanoparticle technology to produce vaccine candidates aimed at eliciting robust immune responses. While the company has gained significant attention for its work during the COVID-19 pandemic, its research and development efforts extend to other infectious diseases as well, positioning Novavax as a key player in the global effort to combat emerging health threats through vaccination.

Summarized from source with an LLMView SourceSector: Technology

Revenue Performance

In the fourth quarter of 2024, Novavax Inc generated $88 million in total revenue, down from $291 million in Q4 2023. For the full year 2024, total revenue was $682 million, compared to $984 million in the previous year. Product sales decreased to $190 million for the year, primarily due to lower sales under APA agreements.

Sanofi Partnership Milestones

Novavax Inc reached a $50 million milestone under its agreement with Sanofi related to the pediatric clinical trial database lock for the first cohort. Additionally, the company anticipates a $175 million milestone payment upon approval of its COVID-19 vaccine Biologics License Application (BLA) by April 2025, with further opportunities for additional milestone payments as the partnership progresses.

Cost Reductions and Asset Sale

The company completed the sale of its Czech Republic manufacturing facility to Novo Nordisk for $200 million, resulting in a gain of $52 million. This sale is expected to reduce annual costs by approximately $80 million. Additionally, cost of sales and SG&A expenses decreased significantly compared to the previous year.

Strong Cash Position and Financial Guidance

Novavax Inc concluded 2024 with over $1 billion in cash and accounts receivables. For the full year 2025, the company provided financial guidance expecting combined R&D and SG&A expenses between $475 million and $525 million, and projected adjusted licensing, royalties, and other revenue between $300 million and $350 million.

Summarized from source with an LLMView Source

Key figures

-20.8%1Y

-67.8%3Y

-92.7%5Y

Performance

76.1%1Y

100%3Y

107%5Y

Volatility